To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.
Remuneration report 2025 for Initiator Pharma A/S
Initiator Pharma’s Remuneration Report 2025 has now been published and is available on the company ́s home page.
Ersättningsrapport 2025 för Initiator Pharma A/S
Initiator Pharmas ersättningsrapport for 2025 har nå publicerats och finns tillgänglig på bolagets hemsida.
INITIATOR PHARMA: RAPPORT FÖR FÖRSTA KVARTALET 2026
Höjdpunkter under första kvartalet 2026
Initiator Pharma progresses patient enrollment in Phase 2a vulvodynia study
Initiator Pharma A/S, a clinical-stage biotech company, today announced good progress in patient enrollment in its Phase 2a clinical proof-of-concept study evaluating pudafensine in women suffering from the genital pain condition, vulvodynia.
Initiator Pharma rapporterar framsteg i patientrekryteringen till fas 2a-studie i vulvodyni
Initiator Pharma A/S, ett bioteknikbolag i klinisk fas, meddelar idag goda framsteg i patientrekryteringen till bolagets kliniska fas 2a proof-of-concept-studie som utvärderar pudafensine hos kvinnor med det genitala smärttillståndet vulvodyni.
Årsredovisning 2025 för Initiator Pharma A/S
Initiator Pharmas årsredovisning för 2025 har nå publicerats och finns tillgänglig på bolagets hemsida.
Annual report 2025 for Initiator Pharma A/S
Initiator Pharma’s Annual Report 2025 has now been published and is available on the company ́s home page.
Initiator Pharma to fully prioritize pudafensine
Initiator Pharma A/S, a clinical-stage biotech company, today announced that the company has decided to focus fully on its most promising drug candidate, pudafensine, which is being developed for both vulvodynia and organic erectile dysfunction (ED). As part of this prioritization, the company will discontinue further development of IP2018.